SCHEMBL3609296

SCHEMBL3609296

[CH2][C@@H]1COCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1696342 1.00
SCHEMBL196697 1.00
SCHEMBL12361216 0.71 MEN1 (0.33)
SCHEMBL306399 0.69
SCHEMBL16926 0.69
SCHEMBL6999 0.69
SCHEMBL31741248 0.69
SCHEMBL4733761 0.69
SCHEMBL293705 0.69
SCHEMBL28773918 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110248949-A Immunoproteasome inhibitor 普林斯匹亚生物制药公司 2019-09-17 CN disclosed
CN-106661039-A TYK2 inhibitors and uses thereof 林伯士拉克许米公司 2017-05-10 CN disclosed
US-20100029696-A1 INDOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2010-02-04 US disclosed
US-20090137615-A1 INDAZOLYLAMINO QUINAZOLINE DERIVATIVES AS ANTITUMOUR AGENTS ASTRAZENECA AB (SE) 2009-05-28 US disclosed
CN-101171245-A Indolylamino quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2008-04-30 CN disclosed
CN-101171244-A Indazolylaminoquinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2008-04-30 CN disclosed
US-20070015743-A1 Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2007-01-18 US disclosed
CN-1882572-A Quinazoline derivatives as antitumor agents ASTRAZENECA AB (SE) 2006-12-20 CN disclosed
EP-1664029-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS AstraZeneca AB (SE) 2006-06-07 EP disclosed
WO-2005026152-A1 QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS ASTRAZENECA AB (SE) 2005-03-24 WO disclosed